Tina Garyantes

Dr. Tina Garyantes is the Vice President of Therapeutics at Chromocell, a research based therapeutics and flavors company, where she is responsible for most of their research functions and their recently announced multi-million dollar collaboration with Astellas. Prior to joining Chromocell, she was CEO of MaxSAR which focused on a high throughput approach to expanding chemical diversity. She also was global head of Assay Development and Screening at Sanofi, particularly Phenotypic and Image Based Screening with therapeutic responsibilities in Fibrosis and Oncology. Tina invented the virtual well plate while at Merck, a derivative of which is now being marketing by Curiox, and developed the first clinical instrument for fine structure analysis of DNA at Ciba-Corning Diagnostics which was used at the Mayo Clinic.